- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
The FDA has approved bemotrizinol as a new sunscreen ingredient, a development that follows years of advocacy by groups like the EWG and its use in Europe.
2 reports, 2 independent
Updated Jun 10
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA has approved bemotrizinol as a new sunscreen ingredient, a development that follows years of advocacy by groups like the EWG and its use in Europe.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approves bemotrizinol for sunscreen use, citing EWG advocacy and European use.1 source
FDA approved Bemotrizinol, regulating sunscreen as a drug, and comparing its status to Japan.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.